2024-20550. Medical Devices; Immunology and Microbiology Devices; Classification of the Whole Exome Sequencing Constituent Device  

  • Table 1—Whole Exome Sequencing Constituent Device Risks and Mitigation Measures

    Identified risks to health Mitigation measures
    Inaccurate test results and failure to provide results Certain design verification and validation, including certain analytical studies and clinical studies; and Certain labeling information, including certain performance information and device limitations.
    Incorrect application or interpretation of results Certain design verification and validation, including certain clinical studies; and Certain labeling information, including certain performance information and device limitations.
    User error and improper use of the device Certain design verification and validation, including certain analytical studies and clinical studies; and Certain labeling information, including certain performance information and device limitations.

Document Information

Effective Date:
9/11/2024
Published:
09/11/2024
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final amendment; final order.
Document Number:
2024-20550
Dates:
This order is effective September 11, 2024. The classification was applicable on December 23, 2020.
Pages:
73565-73568 (4 pages)
Docket Numbers:
Docket No. FDA-2024-N-4018
Topics:
Biologics, Laboratories, Medical devices
PDF File:
2024-20550.pdf
CFR: (1)
21 CFR 866